This Pharma Company Stays Innovative by Doing Two Things
Harvard Business Review
MARCH 14, 2017
For industries that depend on innovation, sustaining it is a constant challenge. These two actions cost almost nothing compared to vast sums often spent — and arguably, often wasted — on efforts to foster innovation. Roivant was addressing some sobering realities: In 2016, only 22 new drugs were approved by the U.S.
Let's personalize your content